- Home
- / Oxford Pharmagenesis
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oxford Pharmagenesis financials data including stock price, CreditSafe score, income statement, and balance sheet.
Revenue
£38.6 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
| Revenue | 25.9M | 32.3M | 38.6M |
| Cost of goods sold | 14.2M | 17.6M | 20.1M |
| Gross profit | 11.7M | 14.7M | 18.5M |
| Gross profit margin, % | 45.3% | 45.6% | 47.9% |
| General and administrative expense | 6.6M | 7.9M | 9.6M |
| Operating expense total | 6.6M | 7.9M | 9.6M |
| EBIT | 5.2M | 6.9M | 8.9M |
| EBIT margin, % | 20.0% | 21.2% | 23.0% |
| Investment income | 22.7K | 54.8K | 20.4K |
| Pre tax profit | 5.2M | 6.8M | 8.9M |
| Income tax expense | 989.7K | 1.3M | 1.8M |
| Net Income | 4.2M | 5.6M | 7.0M |